Oncocyte (NASDAQ:IMDX) Stock Price Up 0.9% – What’s Next?

Oncocyte Corp (NASDAQ:IMDX)’s share price was up 0.9% on Thursday . The stock traded as high as $6.02 and last traded at $5.74. Approximately 141,945 shares changed hands during mid-day trading, a decline of 43% from the average daily volume of 250,938 shares. The stock had previously closed at $5.69.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IMDX. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a report on Wednesday, June 24th. Wall Street Zen raised shares of Oncocyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $12.00.

Oncocyte Trading Up 0.9%

The company has a market capitalization of $185.34 million, a P/E ratio of -3.88 and a beta of 1.76. The firm’s 50 day moving average price is $5.43 and its two-hundred day moving average price is $5.44.

Oncocyte (NASDAQ:IMDX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.28) EPS for the quarter. The firm had revenue of $0.03 million for the quarter.

Insider Transactions at Oncocyte

In other Oncocyte news, major shareholder Broadwood Partners, L.P. purchased 250,923 shares of the business’s stock in a transaction on Monday, April 27th. The shares were purchased at an average cost of $3.64 per share, with a total value of $913,359.72. Following the transaction, the insider directly owned 12,684,884 shares of the company’s stock, valued at $46,172,977.76. This represents a 2.02% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 753,045 shares of company stock valued at $2,685,120. 2.21% of the stock is currently owned by insiders.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.